FindTrial
Sign In

Palliative Radiotherapy in Skeletal Metastasis

Prospective Registry for Skeletal Metastasis treated with Palliative intent Radiation - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/08/072042
Enrollment
200
Registered
2024-08-07
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast Health Condition 2: C60- Malignant neoplasm of penis Health Condition 3: C62- Malignant neoplasm of testis Health Condition 4: C15-C26- Malignant neoplasms of digestive organs Health Condition 5: C69-C72- Malignant neoplasms of eye, brain and other parts of central nervous system Health Condition 6: C51-C58- Malignant neoplasms of female genital organs Health Condition 7: C76-C80- Malignant neoplasms of ill-defined, other secondary and unspec

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Control Intervention1: Nil: Nil Control Intervention2: Nil: Nil

Sponsors

Homi Bhabha Cancer Hospital and Research Center, Tata Memorial Centre, Visakhapatnam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Patients with histologically confirmed malignancy with symptomatic metastatic bone disease detected on cross sectional imaging b. If bone metastases are asymptomatic or minimally symptomatic (without opioid need) will be considered as high risk bone metastases if any of the following criteria is met: 1. More than 50% cortical destruction 2. More than 3 cm maximum diameter 3. Axila cortical involvement more than 3 cm 4. Multifocal lytic disease

Exclusion criteria

Exclusion criteria: 1. Patients who had previously received radiation therapy in the study region concerned. 2. Patients with any comorbidities that attributes to the present symptoms (intervertebral disc prolapse, spinal cord compression, and fractures post-spinal fixation) 3. Leptomeningeal disease. 4. Serious medical co-morbidities that preclude RT. 5. Patients who are diagnosed with prostate & haematolymphoid malignancy.

Design outcomes

Primary

MeasureTime frame
To Assess incidence of Skeletal Related events (SRE)Timepoint: 6 months—

Secondary

MeasureTime frame
To document post-radiation acute toxicitiesTimepoint: 3 months;To document post-radiation late toxicitiesTimepoint: 12 months;To Evaluate pain response in patients with Symptomatic bone metastasisTimepoint: 6 months;To evaluate patterns of analgesic usage in patients with symptomatic bone metastasisTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr Rohit Avinash Vadgaonkar

Homi Bhabha Cancer Hospital and Research Center

suneethalellapalli@gmail.com918555014754

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026